Versant Capital Management’s Revolution Medicines RVMD Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$103K Buy
500
+6
+1% +$1.19K 0.01% 916
2026
Q2
$92.5K Buy
494
+34
+7% +$4.97K 0.01% 979
2026
Q1
$44.7K Buy
460
+314
+215% +$31.7K ﹤0.01% 1300
2025
Q4
$11.6K Hold
146
– – ﹤0.01% 1930
2025
Q3
$6.82K Sell
146
-81
-36% -$3.17K ﹤0.01% 2089
2025
Q2
$8.35K Buy
227
+205
+932% +$7.88K ﹤0.01% 1968
2025
Q1
$778 Buy
22
+13
+144% +$528 ﹤0.01% 2385
2024
Q4
$394 Buy
+9
New +$454 ﹤0.01% 2292
2023
Q4
– Sell
-20
Closed -$554 – 1997
2023
Q3
$554 Hold
20
– – ﹤0.01% 1671
2023
Q2
$535 Buy
+20
New +$491 ﹤0.01% 1819

Other funds holding RVMD

Versant Capital Management's RVMD Position: Q3 2026 in Review

Versant Capital Management increased its Revolution Medicines (RVMD) stake by 1.2% in Q3 2026, buying an estimated $1.19K and bringing the position to 500 shares worth $103K. The position accounts for 0.01% of the portfolio, ranked #916.

Versant Capital Management first reported a position in RVMD in Q2 2023 and has held it in 10 quarters since. 756 funds tracked by Wall St. Rank hold RVMD as of Q3 2026.

  • Versant Capital Management held 500 shares of Revolution Medicines worth $103K as of Q3 2026.
  • Versant Capital Management bought 6 Revolution Medicines shares in Q3 2026, an estimated $1.19K.
  • Revolution Medicines made up 0.01% of Versant Capital Management's portfolio in Q3 2026, its #916 holding.
  • Versant Capital Management first reported a position in Revolution Medicines in Q2 2023 and has held it in 10 quarters since.
  • 756 funds tracked by Wall St. Rank held Revolution Medicines as of Q3 2026.

Based on Versant Capital Management's 13F filing for Q3 2026, filed 2 Oct 2026.